Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding

Jiwon Choi, Rajiv Gandhi Govindaraj, Jae Wook Hyeon, Kyungro Lee, Song Ling Ma, Su Yeon Kim, Jeongmin Lee, Kyoung Tai No

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Transition of a physiological folded prion (PrPC) into a pathogenic misfolded prion (PrPS c) causes lethal neurodegenerative disorders and prion diseases. Antiprion compounds have been developed to prevent this conversion; however, their mechanism of action remains unclear. Recently, we reported two antiprion compounds, BMD29 and BMD35, identified by in silico and in vitro screening. In this study, we used extensive explicit-solvent molecular dynamics simulations to investigate ligand-binding inhibition by antiprion compounds in prion folding over misfolding behavior at acidic pH. The two antiprion compounds and the previously reported GN8 compound resulted in a remarkably stabilized intermediate by binding to the hotspot region of PrPC, whereas free PrPC and the inactive compound BMD01 destabilized the structure of PrPC leading to the misfolded form. The results uncovered a secondary structural transition of free PrPC and transition suppression by the antiprion compounds. One of the major misfolding processes in PrPC, alternation of hydrophobic core residues, disruption of intramolecular interactions, and the increase in residue solvent exposure were significantly inhibited by both antiprion compounds. These findings provide insights into prion misfolding and inhibition by antiprion compounds.

Original languageEnglish
Pages (from-to)907-917
Number of pages11
JournalChemical Biology and Drug Design
Volume89
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Prions
Neurodegenerative Diseases
Prion Diseases
Molecular Dynamics Simulation
Computer Simulation
Molecular dynamics
Ligands
Screening
Computer simulation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine

Cite this

Choi, Jiwon ; Govindaraj, Rajiv Gandhi ; Hyeon, Jae Wook ; Lee, Kyungro ; Ma, Song Ling ; Kim, Su Yeon ; Lee, Jeongmin ; No, Kyoung Tai. / Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding. In: Chemical Biology and Drug Design. 2017 ; Vol. 89, No. 6. pp. 907-917.
@article{54aeecabfbd04e129f408ba2e6836016,
title = "Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding",
abstract = "Transition of a physiological folded prion (PrPC) into a pathogenic misfolded prion (PrPS c) causes lethal neurodegenerative disorders and prion diseases. Antiprion compounds have been developed to prevent this conversion; however, their mechanism of action remains unclear. Recently, we reported two antiprion compounds, BMD29 and BMD35, identified by in silico and in vitro screening. In this study, we used extensive explicit-solvent molecular dynamics simulations to investigate ligand-binding inhibition by antiprion compounds in prion folding over misfolding behavior at acidic pH. The two antiprion compounds and the previously reported GN8 compound resulted in a remarkably stabilized intermediate by binding to the hotspot region of PrPC, whereas free PrPC and the inactive compound BMD01 destabilized the structure of PrPC leading to the misfolded form. The results uncovered a secondary structural transition of free PrPC and transition suppression by the antiprion compounds. One of the major misfolding processes in PrPC, alternation of hydrophobic core residues, disruption of intramolecular interactions, and the increase in residue solvent exposure were significantly inhibited by both antiprion compounds. These findings provide insights into prion misfolding and inhibition by antiprion compounds.",
author = "Jiwon Choi and Govindaraj, {Rajiv Gandhi} and Hyeon, {Jae Wook} and Kyungro Lee and Ma, {Song Ling} and Kim, {Su Yeon} and Jeongmin Lee and No, {Kyoung Tai}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/cbdd.12916",
language = "English",
volume = "89",
pages = "907--917",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",
number = "6",

}

Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding. / Choi, Jiwon; Govindaraj, Rajiv Gandhi; Hyeon, Jae Wook; Lee, Kyungro; Ma, Song Ling; Kim, Su Yeon; Lee, Jeongmin; No, Kyoung Tai.

In: Chemical Biology and Drug Design, Vol. 89, No. 6, 01.06.2017, p. 907-917.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding

AU - Choi, Jiwon

AU - Govindaraj, Rajiv Gandhi

AU - Hyeon, Jae Wook

AU - Lee, Kyungro

AU - Ma, Song Ling

AU - Kim, Su Yeon

AU - Lee, Jeongmin

AU - No, Kyoung Tai

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Transition of a physiological folded prion (PrPC) into a pathogenic misfolded prion (PrPS c) causes lethal neurodegenerative disorders and prion diseases. Antiprion compounds have been developed to prevent this conversion; however, their mechanism of action remains unclear. Recently, we reported two antiprion compounds, BMD29 and BMD35, identified by in silico and in vitro screening. In this study, we used extensive explicit-solvent molecular dynamics simulations to investigate ligand-binding inhibition by antiprion compounds in prion folding over misfolding behavior at acidic pH. The two antiprion compounds and the previously reported GN8 compound resulted in a remarkably stabilized intermediate by binding to the hotspot region of PrPC, whereas free PrPC and the inactive compound BMD01 destabilized the structure of PrPC leading to the misfolded form. The results uncovered a secondary structural transition of free PrPC and transition suppression by the antiprion compounds. One of the major misfolding processes in PrPC, alternation of hydrophobic core residues, disruption of intramolecular interactions, and the increase in residue solvent exposure were significantly inhibited by both antiprion compounds. These findings provide insights into prion misfolding and inhibition by antiprion compounds.

AB - Transition of a physiological folded prion (PrPC) into a pathogenic misfolded prion (PrPS c) causes lethal neurodegenerative disorders and prion diseases. Antiprion compounds have been developed to prevent this conversion; however, their mechanism of action remains unclear. Recently, we reported two antiprion compounds, BMD29 and BMD35, identified by in silico and in vitro screening. In this study, we used extensive explicit-solvent molecular dynamics simulations to investigate ligand-binding inhibition by antiprion compounds in prion folding over misfolding behavior at acidic pH. The two antiprion compounds and the previously reported GN8 compound resulted in a remarkably stabilized intermediate by binding to the hotspot region of PrPC, whereas free PrPC and the inactive compound BMD01 destabilized the structure of PrPC leading to the misfolded form. The results uncovered a secondary structural transition of free PrPC and transition suppression by the antiprion compounds. One of the major misfolding processes in PrPC, alternation of hydrophobic core residues, disruption of intramolecular interactions, and the increase in residue solvent exposure were significantly inhibited by both antiprion compounds. These findings provide insights into prion misfolding and inhibition by antiprion compounds.

UR - http://www.scopus.com/inward/record.url?scp=85012118611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012118611&partnerID=8YFLogxK

U2 - 10.1111/cbdd.12916

DO - 10.1111/cbdd.12916

M3 - Article

C2 - 27933736

AN - SCOPUS:85012118611

VL - 89

SP - 907

EP - 917

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

IS - 6

ER -